Sensory Restoration After DIEP Flap Neurotization

February 7, 2024 updated by: Johns Hopkins University

The Effect of DIEP Flap Neurotization on Sensory Restoration After Breast Reconstruction

Common goals of breast reconstruction include obtaining satisfactory breast symmetry, softness, and appropriate size and shape. Advances in surgical techniques have prompted a new goal: achieving breast sensation after reconstructive surgery. This desire has led the surgical community to investigate operative techniques for achieving this goal. However, few studies have examined the effectiveness of breast sensory restoration.

Sensory nerves are nerves responsible for sensation from skin. When a sensory nerve is cut, sensation is lost to the area supplied by the nerve. In the case of Breast reconstruction this involves the nerves supplying the skin overlying breast(s). 'Neurotization' refers to regeneration of the nerve after it has been cut. This means that the cut nerve is being repaired in order to restore its function. In Neurotization this repair is carried out using a new "source". In this case, the investigators want to restore function of the nerves that supply the skin overlying the breast(s).

The investigators will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.

The Avance® Nerve graft is a nerve graft material that has been produced by Axogen, Inc. The graft is made by processing donated human nerves. This graft is used during neurotization to bridge the gap and join the nerve from the abdominal tissue to the nerve in the chest wall. The use of the graft helps the body to attach these 2 nerves and improves nerve repair.

When neurotization is done without the nerve graft there is a possibility that the surgeon may require extra nerve material to join the 2 nerves. Traditionally, in this case the surgeon would have to obtain a separate donor nerve from another part of the patient's body. This technique carries the risk of complications to part of the body that the separate donor nerve was obtained from - loss of sensation, infection or neuroma formation (an abnormal growth of nerve tissue that can cause pain, burning or tingling sensation, numbness). The Avance nerve graft avoids the need for the additional donor nerve and the possible complications associated with it.

The Avance® Nerve Graft is currently being used in some women during breast reconstruction surgery, however the effectiveness of this procedure in improving the restoration of sensation has not been proven.

Women undergoing reconstruction of one breast and at the same time using the women's own tissue as part of standard clinical care, may join.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

156

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. All patients presenting to Johns Hopkins who have had or will have mastectomy (therapeutic or prophylactic) and are planning to undergo unilateral mastectomy followed by breast reconstruction with autologous deep inferior epigastric perforator flap (DIEP) will be included.

    These patients will then be randomized in either of two treatment modalities:

    • Treatment Modality 1: Breast reconstruction with DIEP flap and neurotization.
    • Treatment Modality 2: Breast reconstruction with DIEP flap but without neurotization.
  2. 18 years of age and older
  3. The patient is aware of the nature of her malignancy if a malignancy has been diagnosed; understands the study purpose, requirements, and risks; and is able and willing to sign an informed consent.

Exclusion Criteria:

  1. Autologous reconstruction where the flap is buried.
  2. Exclusion criteria will encompass any patient with: diabetic neuropathy, thyroid disorders, collagen vascular disease, alcoholism, pernicious anemia, or any other severe underlying peripheral neuropathy including chemotherapy-induced neuropathy or neuropathy induced by other medications.
  3. Pregnant or lactating women will be excluded from this study.
  4. Women with recurrent breast cancer will be excluded.
  5. Women with previous reconstructive procedures or who have previously undergone lumpectomy with radiation will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Neurotized Patients
Neurotization will be performed at the time of reconstruction.
We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.
No Intervention: Non-Neurotized Patients
No Neurotization will be performed at the time of reconstruction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
12-month Breast sensation as assessed by the AcroValTM device
Time Frame: 12-months after DIEP Flap neurotization
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
12-months after DIEP Flap neurotization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breast sensation at 6 months as assessed by the AcroValTM device
Time Frame: 6 months after DIEP flap breast reconstruction
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
6 months after DIEP flap breast reconstruction
Breast sensation at 18 months as assessed by the AcroValTM device
Time Frame: 18 months after DIEP flap breast reconstruction
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
18 months after DIEP flap breast reconstruction
Breast sensation at 24 months as assessed by the AcroValTM device
Time Frame: 24 months after DIEP flap breast reconstruction
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
24 months after DIEP flap breast reconstruction
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 6 months after DIEP flap breast reconstruction

The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:

i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome

and 3 well-being sub-domains:

i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being

Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

6 months after DIEP flap breast reconstruction
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 12 months after DIEP flap breast reconstruction

The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:

i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome

and 3 well-being sub-domains:

i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being

Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

12 months after DIEP flap breast reconstruction
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 18 months after DIEP flap breast reconstruction

The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:

i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome

and 3 well-being sub-domains:

i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being

Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

18 months after DIEP flap breast reconstruction
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 24 months after DIEP flap breast reconstruction

The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:

i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome

and 3 well-being sub-domains:

i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being

Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

24 months after DIEP flap breast reconstruction
General health-related quality of life using the SF-12
Time Frame: 6 months after DIEP flap breast reconstruction
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
6 months after DIEP flap breast reconstruction
General health-related quality of life using the SF-12
Time Frame: 12 months after DIEP flap breast reconstruction
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
12 months after DIEP flap breast reconstruction
General health-related quality of life using the SF-12
Time Frame: 18 months after DIEP flap breast reconstruction
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
18 months after DIEP flap breast reconstruction
General health-related quality of life using the SF-12
Time Frame: 24 months after DIEP flap breast reconstruction
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
24 months after DIEP flap breast reconstruction
Change in breast sensation as assessed by the AcroValTM device
Time Frame: Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction
Change in breast sensation from baseline, measured in cutaneous thresholds using the AcroValTM device.
Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction
Change in breast-specific health-related quality of life using the Breast-Q®
Time Frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction

The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains:

i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome

and 3 well-being sub-domains:

i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being

Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
Change in general health-related quality of life using the SF-12
Time Frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Gedge D Rosson, MD, Johns Hopkins University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2020

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

August 26, 2020

First Submitted That Met QC Criteria

August 26, 2020

First Posted (Actual)

August 31, 2020

Study Record Updates

Last Update Posted (Actual)

February 9, 2024

Last Update Submitted That Met QC Criteria

February 7, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • IRB00167074

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on DIEP Flap Neurotization

3
Subscribe